(all amounts are in Canadian dollars)
-
Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share
-
Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share
-
Cash as of April 30, 2026, $0.7 million
-
Company remains debt-free
QUÉBEC, June 29, 2026 /CNW/ – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026.
Devonian Inc. (CNW Group/Devonian Health Group Inc.)
”We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline”, said Dr. André P. Boulet, PhD, Chief…
